Tempus AI (Nasdaq: TEM) secured up to USD 9.5 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop and clinically validate an autonomous AI system for heart failure care under the agency's ADVOCATE program.
The award will support development of the agent and a multi-center prospective study intended to assess its use in clinical workflows. Tempus said the system will integrate electronic health record data with information from home-based monitoring devices and support functions including symptom monitoring, medication coordination, virtual rehabilitation, and scheduling.
The platform will build on several existing Tempus products, including Olivia, its patient-facing health concierge; Tempus Next, a care-gap identification platform that the company said has screened more than 2.7 million cardiology patients; and three FDA-cleared ECG-based AI products.
Tempus received US FDA clearance for an ECG-based AI product in August 2026 designed to identify patients showing signs associated with pulmonary hypertension, marking its third cleared ECG-AI product in cardiovascular care.